February 2025 – Delex Healthcare Group Inc. (DELEX), a rapidly expanding pharmaceutical and healthcare company, continues to make significant strides in addressing critical care challenges. Founded in 2017 and incorporated in Delaware, USA, DELEX specializes in the development, distribution, and marketing of pharmaceutical products through its subsidiaries, including DELEX Pharma International Inc. (DELEX Pharma), DLX Holdings Corp., and JMN Brother’s Pharma Limited Inc.
DELEX’s flagship subsidiary, Delex Pharma International Inc., established in 2010 and based in Manila, Philippines, serves as a cornerstone of the company’s growing footprint in the global healthcare market. With over 30 Products approved by the Philippines FDA, an experienced team of over 100 sales and marketing professionals and more than 1,000 distribution channels spanning hospitals, pharmacies, and healthcare centers across the Philippines, Delex Pharma is poised to expand its reach to meet the increasing demand for advanced medical solutions in critical care environments.
DELEX is committed to closing the gaps in critical care treatment. The company’s mission is to provide alternative, effective drugs designed to address the specific needs of patients in Intensive Care Units (ICU). By focusing on high-demand, life-saving therapies, DELEX is helping to ensure better outcomes for critically ill patients while improving the overall quality of care provided in these high-pressure medical settings.
“Our commitment is simple: to meet the gaps in critical care and offer innovative solutions where they are most needed,” said [CEO/Spokesperson Name], CEO of Delex Healthcare Group Inc. “By continuing to develop and distribute cutting-edge pharmaceutical products, we are proud to contribute to the improvement of healthcare delivery, particularly in life-critical situations that demand timely, effective intervention.”
As part of its growth strategy, DELEX plans to expand its presence in both established and emerging healthcare markets. Through strategic partnerships, research and development initiatives, and the continued expansion of its distribution network, the company is positioned for strong future growth in the global pharmaceutical industry.
DELEX Pharma, a subsidiary of DELEX Healthcare Group, Inc., is a leading distributor of pharmaceutical and healthcare products in the Philippines. The company is committed to delivering high-quality, reliable products that meet the needs of healthcare providers and patients nationwide. With a strong focus on operational excellence, innovation, and customer satisfaction, DELEX Pharma is set for sustained growth and market leadership.
This press release contains forward-looking statements regarding DELEX Pharma’s strategic direction and growth prospects. These statements are based on current expectations and assumptions, which are subject to risks and uncertainties. Actual results may differ materially from those expressed in the forward-looking statements. Investors are advised to conduct their own due diligence and consult with a financial advisor before making investment decisions.
